BioSpace News Archive

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a research collaboration with MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb.

CND Life Sciences (cndlifesciences.com), an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, will participate in the 2021 virtual Biotech Showcase taking place during the 39th Annual J.P. Morgan Healthcare Conference (January 11-14, 2021).

Expanded In Vitro Modeling Tools Will Enable Researchers to Better Understand the Effects of Advanced Biologics and Gene Therapies

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate virtually in a Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference, being held on January 11-14, 2021.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat during the January 11th-14th H.C. Wainwright BioConnect 2021 Virtual Conference.

AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal diseases, issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer.

Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors.

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”) today announced the first patient was dosed in OMS-104, an investigator-initiated Phase 2 trial evaluating TAVO™ (tavokinogene telseplasmid), the Company’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy administered using its gene delivery platform (gene electrotransfer)

The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on autho